Cover Image
市場調查報告書

5-羥色胺受體6 (5-HT6,血清素受體6,HTR6) - 開發中產品分析

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 358699
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
5-羥色胺受體6 (5-HT6,血清素受體6,HTR6) - 開發中產品分析 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 81 Pages
簡介

5-HT6受體是5-HT受體的亞型,與內因性神經傳達物質血清素結合。5-HT6受體在老年癡呆症和其他類型的癡呆症、肥胖中都扮演著重要的角色。

本報告提供5-羥色胺受體6 (5-HT6,血清素受體6,HTR6)的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品
  • 階段不明的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Adamed Sp. z o.o.
  • Avineuro Pharmaceuticals, Inc.
  • Axovant Sciences Ltd.
  • Biotie Therapies Corp.
  • Galenea Corp.
  • H. Lundbeck A/S
  • Reviva Pharmaceuticals Inc.
  • Suven Life Sciences Ltd.
  • Teva Pharmaceutical Industries Ltd.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1083TDB

Summary:

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2017, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic and cholinergic neurotransmission in brain, whereas activation enhances GABAergic signaling in a widespread manner. Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimer's disease and other forms of dementia and obesity. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 2, 11 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Metabolic Disorders which include indications Alzheimer's Disease, Schizophrenia, Psychiatric Disorders, Anxiety Disorders, Mild Cognitive Impairment, Neurology, Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (Manic Depression), Cognitive Disorders, Dementia, Depression, Lewy body Dementia, Major Depressive Disorder, Movement Disorders, Neurodegenerative Diseases, Obesity, Parkinson's Disease, Pervasive Developmental Disorder (PDD), Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Tourette Syndrome and Vascular Injury.

Furthermore, this report also reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
  • The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Overview
    • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Companies Involved in Therapeutics Development
    • Acorda Therapeutics Inc
    • Adamed Sp z oo
    • Avineuro Pharmaceuticals Inc
    • Axovant Sciences Ltd
    • Celon Pharma SA
    • Galenea Corp
    • H. Lundbeck A/S
    • Reviva Pharmaceuticals Inc
    • Suven Life Sciences Ltd
    • Teva Pharmaceutical Industries Ltd
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Drug Profiles
    • ADN-1184 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADN-2013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADN-3662 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-3208 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-0189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-3085 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-3205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-322 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-492 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • intepirdine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • landipirdine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LuAF-35700 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-5063 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize 5-HT6 Receptor for Mood Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target 5-HT2C and 5-HT6 Receptor for Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-512 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Dormant Products
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Discontinued Products
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension
      • Sep 26, 2017: Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease
      • Sep 26, 2017: Set-back for Alzheimer's drug in final stage trial
      • Jul 19, 2017: New Preclinical Data for Intepirdine Suggests Potential Neuroprotective Properties
      • Dec 09, 2016: Axovant Sciences Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer's Disease Maintain Independence Longer
      • Dec 09, 2016: Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer's Disease Maintain Independence Longer
      • Dec 05, 2016: Axovant Sciences to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimer's Disease at CTAD 2016
      • Dec 05, 2016: Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimers Disease at CTAD 2016
      • Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
      • Sep 26, 2016: Axovant Sciences Receives FDA Fast-Track Designation for Intepirdine as an Investigational Treatment for Dementia with Lewy Bodies
      • Jul 18, 2016: Axovant Sciences Announces Presentations on Intepirdine and Sponsored Symposium at the 2016 Alzheimers Association International Conference
      • May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
      • Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia
      • Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia
      • Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Acorda Therapeutics Inc, H2 2017
  • Pipeline by Adamed Sp z oo, H2 2017
  • Pipeline by Avineuro Pharmaceuticals Inc, H2 2017
  • Pipeline by Axovant Sciences Ltd, H2 2017
  • Pipeline by Celon Pharma SA, H2 2017
  • Pipeline by Galenea Corp, H2 2017
  • Pipeline by H. Lundbeck A/S, H2 2017
  • Pipeline by Reviva Pharmaceuticals Inc, H2 2017
  • Pipeline by Suven Life Sciences Ltd, H2 2017
  • Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top